& Events
& Events
News
& Events
Oct 13, 2020 Inversago Pharma Appoints Michael D. Harvey, PhD as Senior Vice President, Drug Development
MONTREAL (CANADA) – October 13, 2020 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Michael D. Harvey, PhD as Senior Vice President, Drug Development. In his position, Dr. Michael Harvey will be responsible for overseeing all R&D activities pertaining to CMC, nonclinical development, and regulatory […]
Sep 29, 2020 Inversago Pharma Initiates Clinical Trials, with a Phase 1 study of INV-101, the Company’s Lead Peripheral CB1 Blocker
MONTREAL (CANADA) – September 29, 2020 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has initiated a Phase 1 clinical trial of INV-101, the Company’s peripherally-acting CB1 blocker, which is being developed for the treatment of Prader-Willi syndrome (PWS) and non-alcoholic steatohepatitis (NASH). The trial will evaluate […]
Sep 28, 2020 Media talk about Inversago Pharma
MONTREAL (CANADA) – September 28, 2020 – The Globe & Mail, BioteCanada’s Insights magazine and Endpoints News recently published articles about Inversago Pharma. The Globe & Mail – Investors bet $35-million on Montreal startup’s effort to revive failed class of weight-loss drugs by Sean Silcoff Insights Magazine – Fall 2020, Pages 80-81 – The Peripheral […]
Sep 8, 2020 Inversago Pharma closes US$35M Series B financing round and expands Board of Directors
Funds to pursue development of INV-101 and other promising peripheral CB1 blockers to clinical proof-of-concept, as well as to expand the Company’s operations. Board of Inversago strengthened with the appointment of three new directors. MONTREAL (CANADA) – September 8th, 2020 –Inversago Pharma Inc. (“Inversago” or “the Company”), the peripheral CB1 blockade company, today announced it […]
